Competent_JJ
transcription_NN
initiation_NN
by_IN
RNA_NN
polymerase_NN
II_CD
in_IN
cell-free_JJ
extracts_NNS
from_IN
xeroderma_NN
pigmentosum_NN
groups_NNS
B_NN
and_CC
D_NN
in_IN
an_DT
optimized_VBN
RNA_NN
transcription_NN
assay_NN
._.

The_DT
human_JJ
autosomal_JJ
recessive_JJ
disease_NN
,_,
xeroderma_NN
pigmentosum_NN
-LRB-_-LRB-
XP_NN
-RRB-_-RRB-
,_,
can_MD
result_VB
from_IN
mutations_NNS
in_IN
any_DT
one_CD
of_IN
seven_CD
genes_NNS
,_,
designated_VBN
XPA_NN
through_IN
XPG_NN
._.

Of_IN
these_DT
,_,
the_DT
XPB_NN
and_CC
XPD_NN
genes_NNS
encode_VBP
proteins_NNS
that_WDT
are_VBP
subunits_NNS
of_IN
a_DT
general_JJ
transcription_NN
factor_NN
,_,
TFIIH_NN
,_,
involved_VBN
in_IN
both_CC
nucleotide_NN
excision_NN
repair_NN
-LRB-_-LRB-
NER_NN
-RRB-_-RRB-
and_CC
initiation_NN
of_IN
mRNA_NN
transcription_NN
by_IN
RNA_NN
polymerase_NN
II_CD
._.

In_IN
humans_NNS
,_,
mutation_NN
of_IN
the_DT
XPB_NN
or_CC
XPD_NN
gene_NN
impairs_VBZ
NER_NN
,_,
resulting_VBG
in_IN
hyper-sensitivity_CD
to_TO
sunlight_CD
and_CC
greatly_RB
increased_VBN
skin_NN
tumor_NN
formation_NN
._.

However_RB
,_,
no_DT
transcription_NN
deficiency_NN
has_VBZ
been_VBN
demonstrated_VBN
in_IN
either_CC
XP-B_NN
or_CC
XP-D_NN
._.

We_PRP
have_VBP
employed_VBN
an_DT
optimized_VBN
cell-free_JJ
RNA_NN
transcription_NN
assay_NN
to_TO
analyze_VB
transcription_NN
activity_NN
of_IN
XP-B_NN
and_CC
XP-D_NN
._.

Although_IN
the_DT
growth_NN
rate_NN
was_VBD
normal_JJ
,_,
the_DT
XP-B_NN
and_CC
XP-D_NN
cells_NNS
contained_VBD
reduced_VBN
amounts_NNS
of_IN
TFIIH_NN
._.

Extracts_NNS
prepared_VBN
from_IN
XP-B_NN
and_CC
XP-D_NN
lymphoblastoid_JJ
cells_NNS
exhibited_VBD
similar_JJ
transcription_NN
activity_NN
from_IN
the_DT
adenovirus_NN
major_JJ
late_JJ
promoter_NN
when_WRB
compared_VBN
to_TO
that_DT
in_IN
extracts_NNS
from_IN
normal_JJ
cells_NNS
._.

Thus_RB
,_,
we_PRP
conclude_VBP
that_IN
the_DT
XP-B_NN
and_CC
XP-D_NN
lymphoblastoid_JJ
cells_NNS
do_VBP
not_RB
have_VB
impaired_JJ
RNA_NN
transcription_NN
activity_NN
._.

We_PRP
consider_VBP
the_DT
possible_JJ
consequences_NNS
of_IN
the_DT
reduced_VBN
cellular_JJ
content_NN
of_IN
TFIIH_NN
for_IN
the_DT
clinical_JJ
symptoms_NNS
in_IN
XP-B_NN
or_CC
XP-D_NN
patients_NNS
,_,
and_CC
discuss_VBP
a_DT
'_``
conditional_JJ
phenotype_NN
'_''
that_WDT
may_MD
involve_VB
an_DT
impairment_NN
of_IN
cellular_JJ
function_NN
only_RB
under_IN
certain_JJ
growth_NN
conditions_NNS
._.

